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Abstract
Background: Array genomic hybridization is being used clinically to detect pathogenic copy
number variants in children with intellectual disability and other birth defects. However, there is
no agreement regarding the kind of array, the distribution of probes across the genome, or the
resolution that is most appropriate for clinical use.
Results:  We performed 500 K Affymetrix GeneChip®  array genomic hybridization in 100
idiopathic intellectual disability trios, each comprised of a child with intellectual disability of
unknown cause and both unaffected parents. We found pathogenic genomic imbalance in 16 of
these 100 individuals with idiopathic intellectual disability. In comparison, we had found pathogenic
genomic imbalance in 11 of 100 children with idiopathic intellectual disability in a previous cohort
who had been studied by 100 K GeneChip® array genomic hybridization. Among 54 intellectual
disability trios selected from the previous cohort who were re-tested with 500 K GeneChip® array
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genomic hybridization, we identified all 10 previously-detected pathogenic genomic alterations and
at least one additional pathogenic copy number variant that had not been detected with 100 K
GeneChip® array genomic hybridization. Many benign copy number variants, including one that was
de novo, were also detected with 500 K array genomic hybridization, but it was possible to
distinguish the benign and pathogenic copy number variants with confidence in all but 3 (1.9%) of
the 154 intellectual disability trios studied.
Conclusion:  Affymetrix GeneChip® 500 K array genomic hybridization detected pathogenic
genomic imbalance in 10 of 10 patients with idiopathic developmental disability in whom 100 K
GeneChip® array genomic hybridization had found genomic imbalance, 1 of 44 patients in whom
100 K GeneChip® array genomic hybridization had found no abnormality, and 16 of 100 patients
who had not previously been tested. Effective clinical interpretation of these studies requires
considerable skill and experience.
Background
Chromosomal imbalance has been recognized as the
most frequent cause of intellectual disability (ID) for 50
years [1-3]. Until recently, most of this genomic imbal-
ance was diagnosed by cytogenetic analysis, but studies
over the past few years have found that ID is caused by
constitutional gains or losses of submicroscopic genomic
segments even more often than by microscopically-appar-
ent chromosomal aberrations [4-6]. Our ability to recog-
nize these submicroscopic genomic changes, which are
usually called copy number variants (CNVs), as the most
frequent cause of ID depends on the use of Array Genomic
Hybridization (AGH) (also known as array-comparative
genomic hybridization, chromosomal microarray analy-
sis, or copy number analysis). AGH can survey the entire
genome for imbalance that is 1/100th the size of that
detectable by conventional cytogenetic analysis.
Although AGH is now being used routinely as a clinical
test for the identification of chromosomal imbalance in
people with ID and other birth defects, controversy still
exists regarding the most appropriate platform to use for
this purpose. Initial clinical studies were done with arrays
having a few thousand BACs distributed at 1-3 Mb inter-
vals across the genome or with BACs targeted to regions
where pathogenic submicroscopic deletions or duplica-
tions were known to occur. More recent studies have
shown that arrays with higher resolution and genome-
wide coverage provide better detection rates for patho-
genic CNVs in children with ID and normal cytogenetic
analysis [7-12]. Other methods have identified patho-
genic CNVs that are too small to have been detected by the
array platforms used in most AGH studies [13-15], so
analysis at even higher resolution may be necessary to
detect all pathogenic CNVs in children with ID.
Unfortunately, use of higher resolution AGH for detection
of genomic imbalance is confounded because most CNVs
are not pathogenic. Estimates of the mean number of
apparently benign CNVs per person range from 6-824 in
various studies, depending on the technology used to
identify the variants and the size range used to define a
CNV [16-25]. Sequencing of the complete diploid
genomes of normal individuals has shown that the
number of CNVs per person is actually even greater [26-
29]. Distinguishing these benign CNVs from those that
cause ID and other birth defects is the most serious chal-
lenge to routine clinical use of AGH.
We previously reported our findings using 100 K Affyme-
trix GeneChip® AGH [10,16] to perform a genome-wide
survey of benign and pathogenic CNVs in 100 idiopathic
ID trios, each comprised of an affected child and both
unaffected parents. Here we describe the results of a study
of 100 new idiopathic ID trios, as well as 54 of the trios
tested previously, using 500 K Affymetrix GeneChip®
AGH. We found that higher resolution AGH detected a
larger number of apparently pathogenic CNVs in both
groups. Many benign CNVs, including at least one that
was de novo, were also detected with the 500 K AGH, but
it was possible to distinguish benign and pathogenic
CNVs with confidence in almost all cases.
Results
We performed AGH with 500 K Affymetrix GeneChip®
arrays on 154 children with idiopathic ID and on both
parents of each affected child. Fifty-four of these trios
(called "the 100 K cohort") had previously been studied
with lower-resolution 100 K GeneChip® AGH [10,16]; the
other 100 trios (called "the new cohort") were studied by
AGH for the first time with the 500 K GeneChip® arrays.
Data were analyzed to determine copy number along the
length of all chromosomes except the Y (for which there
are no probes on either the 100 K or 500 K GeneChip®
arrays), and the findings for each child were compared
with those for his or her parents. Autosomal CNVs seen in
the child and in at least one parent were considered likely
to be benign polymorphisms. Autosomal CNVs found in
the child but not in either parent were evaluated by an
independent method to confirm the presence of the CNVBMC Genomics 2009, 10:526 http://www.biomedcentral.com/1471-2164/10/526
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and its de novo occurrence. CNV calls on the X-chromo-
some in a female child were validated by an independent
method if they appeared to have occurred de novo; CNV
calls on the X-chromosome in a male child were validated
by an independent method whether they appeared to be
de novo or to have been inherited from the mother.
We found a total of 4577 hits (putative CNVs including at
least 10 contiguous SNPs called by the SMD software with
a p-value below 1 × 10-8) in the 462 samples (154 trios)
analyzed by 500 K GeneChip® AGH. This is an average of
about 10 hits per sample, which is an underestimate of the
total number of benign CNVs present because of the strin-
gent cutoff used to obtain a false discovery rate of less than
5% (see Methods).
Within the 54 trios who were studied with both platforms,
we found four times as many hits with 500 K AGH as we
did with 100 K AGH (Table 1). The ratio of the number of
putative CNVs called with the 500 K platform to the
number called with the 100 K platform was 11.0 for CNVs
between 100 kb and 200 kb in size but was lower for both
smaller and larger CNVs (4.1 for those < 100 kb and 3.4
for those between 200 kb and 500 kb).
The 4577 putative CNVs called in all 154 trios were sub-
jected to further bioinformatic analysis (see Methods) to
produce a final annotated list of 58 apparently de novo
CNVs and two cases of mosaic trisomy that were called in
50 patients. These apparent genomic imbalances were
subjected to validation by independent methods. Thus, an
apparent de novo CNV call that required independent val-
idation was made in about 1 child in 3. Thirty-three of
these CNVs in 30 patients and both cases of mosaic tri-
somy were confirmed to be de novo by an independent
method and are described in detail below. The other puta-
tive CNVs were found to be present in both of the parents
as well as in the child (false negative AGH calls in the par-
ents) in two instances or could not be confirmed to be
present in the child (false positive AGH calls) in 22
instances. Altogether, false positive CNV calls were made
in 21 (13.6%) of the 154 trios studied and false negative
CNV calls were made in 2 (1.3%) of the 154 trios studied.
In one other trio (Family 5202), an apparent de novo dele-
tion of chromosome 14 called on AGH in the child was
found by FISH to be a duplication of the region in both
parents instead.
Nineteen of 100 children with ID in the new cohort were
found by Affymetrix 500 K GeneChip® AGH to have de
Table 1: Putative CNVs called on 100 K and 500 K AGH in 54 trios tested with both technologies.
Comparison Child to Father Child to Mother
Array 100 K 500 K 100 K 500 K
All CNV Calls Number 125 497 110 501
Number per Child 2.31 9.20 2.04 9.28
Statistical Significance t = 7.18, p < 0.0001 t = 6.67, p < 0.0001
CNV Calls < 100 kb Number 59 237 53 221
Number per Child 1.06 4.39 0.98 4.09
Statistical Significance t = 7.82, p < 0.0001 t = 5.19, p < 0.0001
CNV Calls ≥ 100 kb and < 200 kb Number 13 130 12 146
Number per Child 0.24 2.41 0.22 2.70
Statistical Significance t = 5.39, p < 0.0001 t = 6.27, p < 0.0001
CNV Calls ≥ 200 kb and < 500 kb Number 33 101 25 98
Number per Child 0.61 1.87 0.46 1.81
Statistical Significance t = 4.66, p < 0.0001 t = 5.25, p < 0.0001
Two-tailed statistical significance was calculated with Student's t-test.BMC Genomics 2009, 10:526 http://www.biomedcentral.com/1471-2164/10/526
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novo  genomic imbalance that was confirmed by FISH,
MLPA, AGH on an Agilent® 244 K platform or cytogenetic
re-analysis (Table 2). One of these children (Patient 8056)
had mosaic trisomy 9, and two were found to have de novo
unbalanced reciprocal translocations - a der(10)t
(2;10)(q37;q26.13) in Patient 873 and a der(4)t
(4;8)(p16.1;p23.1) in Patient 5814 - each producing both
a terminal duplication and a terminal deletion identified
by AGH. We found de novo submicroscopic deletions in
13 other patients and de novo submicroscopic duplica-
tions in three other patients. The deletions ranged in size
from 89 kb to 11.0 Mb; six were less than 1 Mb. The dupli-
cations ranged in size from 362 kb to 11.1 Mb; one was
less than 1 Mb.
Using 500 K Affymetrix GeneChip® AGH, we also con-
firmed the genomic imbalance that had previously been
identified in 10 of the 54 ID trios from the 100 K cohort
(Table 3 and Additional File 1: Supplemental Table S1). In
addition, we identified and confirmed by FISH two de
novo CNVs that were not called on the 100 K assay - a 1.6
Mb duplication of 8q23.2-23.3 in Patient 3890 and a 1.5
Mb deletion of 4p16.3 in Patient 4840 (Table 3 and Figure
1).
We found two instances of uniparental disomy (UPD),
diagnosed by the occurrence of mendelian inconsistency
in a region with a normal copy number of 2 [30], among
the 100 ID trios in the new cohort studied by 500 K
Affymetrix GeneChip® AGH (Table 4 and Figures 2A and
2B). Patient 6904 has mosaic paternal isodisomy of most
of the short arm of chromosome 11. Patient 1658 has
maternal UPD 16, being heterodisomic for the central
portion of the chromosome and isodisomic for both ends.
Both cases were confirmed to be disomic with microsatel-
lite markers (Figures 2C and 2D).
We judged the mosaic trisomy 9, both unbalanced recip-
rocal translocations, 11 of the other de novo deletions, and
two of the other de novo duplications found in the new
cohort to be pathogenic (Table 2). A mosaic 107 kb de
novo deletion of chromosome 14 q11.2 (Patient 818) and
a homozygous 89 kb deletion of the HLA-G region that
resulted from transmission by parents who both carried
heterozygous deletions of the same region (Patient 216)
were judged to be benign variants. A 186 kb deletion of
chromosome 21q22.11 (Patient 8619), a 362 kb duplica-
tion of chromosome 22 q11.21 (Patient 9979) and both
cases of UPD (Patients 1658 and 6904) were of uncertain
clinical significance.
Of the two de novo CNVs identified by 500 K Affymetrix
GeneChip® AGH in the 44 children with ID whose 100 K
GeneChip® AGH studies had been interpreted as normal
(Table 3), one is likely to be pathogenic and the other is
of uncertain clinical significance. A 1.5 Mb deletion of
4p16.3 in Patient 4840 is pathogenic because of its size,
the inclusion of two genes that have been implicated in
the Wolf-Hirschhorn syndrome (WHSC1 and WHSC2),
overlap with known pathogenic CNVs, and a compatible
clinical phenotype. The 1.6 Mb duplication of 8q23.2-
23.3 in Patient 3890 is of unknown clinical significance.
It includes no RefSeq genes but involves a large (1.6 Mb)
genomic region, most of which has never been reported to
be polymorphic in normal individuals.
Discussion
Because its detection rate for pathogenic genomic imbal-
ance is much higher than that of conventional cytogenetic
analysis, a consensus has developed that AGH should be
used clinically for the evaluation of patients with ID and
other birth defects [31-38]. It is clear that AGH using "tar-
geted" arrays that only include probes for genomic regions
known to be involved in microdeletion or microduplica-
tion syndromes has substantially lower detection rates for
CNVs that cause ID than AGH using arrays that provide
genome-wide coverage [37,39-41]. Beyond this, however,
there is no agreement regarding the kind of array, the dis-
tribution of probes across the genome, or the resolution
that is most appropriate for clinical use. Although BAC
arrays were initially used, most clinical laboratories now
prefer oligonucleotide arrays because high-quality plat-
forms that produce consistent results are reliably available
from commercial sources. In addition, the use of larger
numbers of smaller probes on oligonucleotide arrays per-
mits more precise delineation of the breakpoints of CNVs
that are detected, which facilitates genotype-phenotype
correlation and clinical interpretation. AGH with a SNP
array provides the additional advantage of generating gen-
otypes that can be used to verify family relationships and
find uniparental disomy as well as a second method (in
addition to hybridization intensity) for identifying
genomic imbalance [10,42-44].
We previously reported that 100 K Affymetrix GeneChip®
AGH is a robust platform for the detection of pathogenic
CNVs in patients with ID [10]. Here we show that the
detection rate of CNVs among such patients is higher with
500 K GeneChip® AGH than with 100 K GeneChip® AGH.
We made about four times as many CNV calls overall with
the 500 K platform as with the 100 K platform when using
the same method of bioinformatic analysis in 54 trios
studied with both technologies (Table 1). We also found
18 instances of pathogenic genomic imbalance in 16 of
100 children with ID and normal cytogenetic analysis
studied by 500 K GeneChip® AGH (Table 2), compared to
11 instances of pathogenic genomic imbalance in 11 of
100 similarly-ascertained children tested by 100 K Gene-
Chip® AGH in our previous study. Although the higher
detection rate we observed with the 500 K platform mayB
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Table 2: Genomic imbalance and uniparental disomy detected by 500K GeneChip® AGH in the new cohort.
Patient Change Location SNP 
Count
Start
→
End
Size (bp) Validation Phenotype RefSeq Genes 
Involved*
Comments Interpretation
9133 Deletion 1p36.32-
p36.33
198 769,185
→ 
3,581,308
2,812,123 FISH, MLPA 9 year-old female with obesity, 
moderate cognitive impairment, 
myoclonus, polyphagia, hypotonia, 
narrow frontal area, deep-set eyes, 
prominent orbital rims, short nose 
with low nasal bridge and upturned 
nasal tip, midface retrusion, short 
philtrum, tented upper lip, thoracic 
kyphosis, small distal phalanges of 
the toes, strabismus, and 11 ribs
~70 genes including 
AGRN, GNB1, PEX10, 
PRKCZ, SKI, and TP73
This CNV is 
included in the 1p36 
deletion syndrome 
critical region, and 
the patient's clinical 
features are 
compatible with 
that syndrome [73].
Pathogenic
873 Duplicatio
n†
2q37 1801 231,577,285
→ 
242,663,303
11,086,018 FISH, MLPA 15 year-old male with severe 
cognitive impairment, birth weight 
< 1st centile, birth length < 1st 
centile, head circumference at birth 
< < 10th centile, hypotonia, 
microcephaly, contractures of hips 
and knees, hypoplastic scrotum, 
undescended testes, prominent, 
cup-shaped ears, narrow bifrontal 
diameter, broad nasal root, 
prominent epicanthal folds, bilateral 
clinodactyly V, ataxic gait, 
progressive joint contractures and 
muscle wasting of lower 
extremities, mixed hearing loss and 
hypoplastic inferior cerebellar 
vermis, partial dysgenesis of corpus 
callosum, and narrow pons and 
brain stem on MRI
~100 genes including 
AGXT, ATG16L1, 
CAPN10, CHRND, 
CHRNG, COL6A3, 
D2HGDH, GBX2, 
HDAC4, MLPH, PDCD1, 
PER2, SAG and UGT1A1
Pathogenic
Deletion† 10q26.13 1920 126,415,527
→ 
134,032,911
7,617,384 ~75 genes including 
ADAM12, CTBP2, 
DOCK1, DPYSL4, FGFR2, 
OAT, and UROSB
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6473 Deletion 4p16.3 337 190,631
→ 
3,277,436
3,086,805 Cytogenetic 
re-analysis, 
FISH
3 year-old male with fetal growth 
retardation, length 2 standard 
deviations below the mean for age, 
weight 3-4 standard deviations 
below the mean, head 
circumference 3-4 standard 
deviations below the mean, global 
developmental delay, seizures, 
triangular face, small jaw, 
posteriorly rotated ears, 2° 
hypospadias, and ataxia
~45 genes including 
ADD1, FGFR3, HTT, 
IDUA, LETM1, PDE6B, 
SH3BP2, and WHSC1
The deletion in this 
patient includes the 
Wolf- Hirschhorn 
syndrome critical 
region, and the 
clinical features are 
compatible with 
that syndrome [74].
Pathogenic
5814 Deletion† 4p16.1-
p16.3
1520 13,255
→ 
8,472,657
8,459,402 Cytogenetic 
re-analysis, 
MLPA
13 month-old female with length 
below the 3rd centile, microcephaly, 
developmental delay, bilateral 
preauricular pits, and submucus 
cleft palate
~90 genes including 
ADD1, ADRA2C, 
CRMP1, EVC
The deletion 
includes the Wolf- 
Hirschorn 
syndrome critical 
region.
Pathogenic
Duplicatio
n†
8p23.1-
p23.3
2579 180,568
→ 
6,898,076
6,717,508 20 genes including 
ARHGEF10, CLN8, 
DLGAP2, and MCPH1
216 Deletion 6p21.33 42 29,937,087
→ 
30,026,517
89,430 MLPA 18 year-old male with postnatal 
onset growth retardation, unilateral 
sensorineural deafness, narrow 
face, bulbous nasal tip and mild 
intellectual disability.
HCG9, MICD and 5 
pseudogenes
Deletion is 
homozygous in 
child, heterozygous 
in both parents (not 
de novo mutation)
Not pathogenic 
for ID
3160 Deletion 6 q21-
q22.31
1596 111,979,175
→ 
121,506,916
9,527,741 FISH 8 year-old female with moderate 
developmental delay, hypotonia, 
microcephaly, brachycephaly, 
epicanthic folds, small ears with 
hypoplastic lobes, and micrognathia
~40 genes including 
ASF1A, COL10A1, FRK, 
FYN, GOPC, HDAC2, 
LAMA4, MCM9, PLN, 
TSPYL1, and WISP3
Pathogenic
2200 Deletion 7p15.3 2320 14,141,506
→ 
24,950,414
10,808,908 FISH 11 1/2 year-old female with head 
circumference at the 2nd centile, 
mild cognitive impairment, 
sensorineural hearing loss, cleft 
palate, craniosynostosis, unilateral 
ptosis and esotropia, orbital rim 
hypoplasia, malar and midface 
hypoplasia, low-set ears with 
incomplete out-folding of superior 
helix, brachydactyly and syndactyly 
of digits, broad thumbs, decreased 
range of motion in elbows, and leg 
length discrepancy
~40 genes including 
DFNA5, DGKB, 
DNAH11, FAM126A, 
HDAC9, IL6, and 
RAPGEF5
Pathogenic
Table 2: Genomic imbalance and uniparental disomy detected by 500K GeneChip® AGH in the new cohort. (Continued)B
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9938 Deletion 7q22.1 170 98,211,585
→ 
100,553,755
2,342,170 FISH 14 year-old female with height < 5th 
centile, weight < 5th centile, head 
circumference < 5th centile, severe 
cognitive impairment, left 
sensorineural hearing loss, close-
set eyes, broad nasal root, marked 
retrognathia, high-arched palate, 
small and narrow feet, short 2-5th 
toes with hypoplastic nails, atrio-
vetricular septal defect, and 
polyarticular arthritis
~70 genes including 
ACHE, ACTL6B, CYP3A5, 
EPO, MUC3A, 
SERPINE1, SMURF1, 
and TFR2
Pathogenic
1594 Duplicatio
n
8 q12 1220 58,388,614
→ 
65,306,097
6,917,483 FISH 1 1/2 year-old female with height > 
97th centile, head circumference at 
2nd-5th centile, developmental delay, 
Duane anomaly, broad glabella, 
epicanthic folds with telecanthus, 
upslanting palpebral fissures, pre-
auricular pits, large ears, atrial and 
ventricular septal defects, and renal 
reflux
15 genes including 
ASPH, CHD7, RAB2A, 
RLBP1L1, TOX, and 
TTPA
Pathogenic
663 Deletion 9 p13.3 800 34,144,847
→ 
38,736,451
4,591,604 FISH 5 1/2 year-old female with height at 
the 5th centile, developmental delay, 
tremor, ocular hypertelorism, 
epicathal folds, double hair whorl, 
bilateral ptosis, short upturned 
nose, flattened philtrum, 
underdeveloped genitalia, and 
pigmentary retinal changes
~75 genes including 
CNTFR, DNAI1, DNAJB5, 
FANCG, GALT, GBA2, 
GNE, GRHPR, NPR2, 
PAX5, RECK, SHB, 
TPM2, UNC13B, and 
VCP
The deleted region 
in this patient is 
completely included 
in the region 
deleted in patient 
9346.
Pathogenic
9346 Deletion 9p11.2-
p13.3
880 33,702,471
→ 
44,744,675
11,042,204 FISH 9 1/2 year-old female with 
moderate cognitive impairment, 
seizures, tremor, cataract, broad 
frontal area with bossing, arched 
eyebrows, low nasal bridge, and 
short, upturned nose
~85 genes including 
CNTFR, DNAI1, DNAJB5, 
FANCG, GALT, GBA2, 
GNE, GRHPR, NPR2, 
PAX5, RECK, SHB, 
TPM2, UNC13B, and 
VCP
The deleted region 
in this patient 
includes the entire 
segment deleted in 
Patient 663.
Pathogenic
523 Deletion 9q34.3 36 139,516,033
→ 
139,814,485
298,452 FISH 4 year-old female with moderate 
developmental delay, hypotonia, 
microcephaly, flat face with 
upslanting palpebral fissures, ocular 
hypotelorism, synophrys, and 
anteverted nares
7 genes including 
EHMT1
This deletion is 
within the critical 
region for the 9q 
subtelomeric 
deletion 
syndrome[75], and 
the child's clinical 
features are 
compatible with 
that syndrome.
Pathogenic
Table 2: Genomic imbalance and uniparental disomy detected by 500K GeneChip® AGH in the new cohort. (Continued)B
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8056 Mosaic 
Trisomy
9 27,641 whole chromosome FISH 2 1/2 year-old male with weight < 
5th centile, developmental delay, 
preauricular skin tags, hypospadias, 
and cryptorchidism
Numerous Clinical features 
compatible with 
mosaic trisomy 9 
syndrome[76,77]
Pathogenic
6904 Uniparenta
l Disomy
11p11.2-
pter
See Table 3 196,767
→ 
44,589,530
44,392,763 Micro-satellite 
markers
11 year-old female with height < 5th 
centile, gross and fine motor delay, 
hypotonia, and moderate mental 
handicap
Numerous Mosaic paternal 
isodisomy; 
phenotype not 
compatible with 
Beckwith-
Wiedemann 
syndrome
Uncertain
9897 Deletion 13q33.3-
q34
530 107,271,189
→ 
109,368,996
2,097,807 FISH 10 year-old female with fetal 
growth retardation, moderate 
cognitive impairment, upslanting 
palpebral fissures, and retrognathia
6 genes including IRS2, 
LIG4, and MYO16
Pathogenic
818 Deletion 14q11.2 24 21,929,710
→ 
>22,036,502
106,792 Fosmid FISH 
(variable)§
6 1/2 year-old male with weight < 
5th centile, height at 5th centile, mild 
cognitive impairment with 
particular delay in language, mild 
mid-face hypoplasia with narrow 
high-arched palate, mild 
micrognathia, pre-auricular pit, 
joint laxity, bilateral clinodactyly of 
hands, and bilateral 2-3 syndactyly 
of toes
Multiple T-cell 
receptor alpha-chain V, 
J, and region genes
Highly polymorphic 
region
Not pathogenic 
for ID
1658 Uniparenta
l Disomy
16 See Table 3 Whole 
chromosom
e
Whole 
chromosom
e
Micro-satellite 
markers
5 year-old female with normal 
growth, severe mental handicap, 
seizures, self-abusive behaviour, 
deep and dark creases under the 
eyes, mild mid-face hypoplasia, and 
large mouth
Numerous Uncertain
2106 Deletion 17q21.31 149 41,049,321
→ 
41,564,451
515,130 FISH 15 year-old male with fetal growth 
retardation, mild cognitive 
impairment, attention deficit 
disorder, sagittal craniosynostosis, 
long face with malar hypoplasia and 
mild rectrognathia, short and 
upslanting palpebral fissures, low-
set ears, unilateral cryptorchidism, 
partial agenesis of the corpus 
callosum, and dilatation of the 
aortic root
5 genes including MAPT The deleted 
segment includes 
the critical region 
for the 17q21.31 
deletion syndrome, 
[78] and this 
patient's clinical 
features are 
compatible with 
that syndrome.
Pathogenic
Table 2: Genomic imbalance and uniparental disomy detected by 500K GeneChip® AGH in the new cohort. (Continued)B
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8619 Deletion 21q22.11 13 33,902,218
→ 
34,087,893
185,675 Agilent 244 K 
AGH
24 year-old male with prenatal and 
postnatal growth retardation, 
moderate to severe intellectual 
disability, severe hypotonia, 
microcephaly, metopic 
craniosynostosis, cleft palate, 
down-slanting palpebral fissures, 
low-set ears, wide nasal base, 
retrognathia, tetralogy of Fallot, 
cryptorchidism, and joint 
hyperextensibility
5 genes including SYNJ1 No polymorphisms 
of region reported
Uncertain
Deletion 22q11.2 110 19,062,809
→ 
19,785,125
722,316 FISH 14 genes including BCR, 
DGCR8, HIRA, MAPK1, 
PRODH, SNAP29, 
SEPT5, SERPIND1, and 
TBX1
The deleted 
segment is included 
in the 22q11 
deletion syndrome 
critical region, and 
the phenotype is 
compatible with 
other reported 
cases of distal 
22q11.2 
microdeletion [79-
81]
Pathogenic
9979 Duplicatio
n
22q11.21 57 19,429,297
→ 
19,791,607
362,310 FISH 20 year-old female with short 
stature, mild mental deficiency, cleft 
palate, and micrognathia
9 genes including PI4KA 
SERPIND1, LZTR1, 
SNAP29
Polymorphic region Uncertain
1128 Duplicatio
n
Xq12-
q21.1
475 67,088,023
→ 
76,204,344
9,116,321 FISH 11 year-old male with normal 
growth, severe developmental 
delay, hypotonia, brachycephaly, 
bilateral epicanthic folds, and 
posteriorly rotated ears with 
hypoplastic helices
~60 genes
including
ABCB7, DLG3, EDA, 
EFNB1, GJB1, IGBP1, 
IL2RG, OPHN1
NAP1L2, NLGN3, 
PHKA1, SLC16A2, TAF1, 
and ZDHHC15
Pathogenic
The table includes all de novo CNVs, mosaic trisomy and UPD detected by 500 K AGH and confirmed by an independent method in 100 children with idiopathic ID. Breakpoints are shown on 
Human Genome Assembly Build 36.1.
* The approximate number of RefSeq genes for each CNV is given, but only the most likely genes for the phenotype are named.
† Unbalanced reciprocal translocation.
§ Interphase FISH in patient 818 showed some cells with no signals, some with 1 signal and some with two signals for a probe in the region of the deletion detected by AGH. This was interpreted 
as evidence of somatic mosaicism for this deletion.
Table 2: Genomic imbalance and uniparental disomy detected by 500K GeneChip® AGH in the new cohort. (Continued)BMC Genomics 2009, 10:526 http://www.biomedcentral.com/1471-2164/10/526
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De novo CNVs detected with 500 K but not 100 K AGH in children with idiopathic ID Figure 1
De novo CNVs detected with 500 K but not 100 K AGH in children with idiopathic ID. The plots show in silico com-
parison of estimated copy number in child versus mother (left) and child versus father (right) at each position along the chro-
mosome. Upper panel: Smoothed copy number plots for chromosome 8 in Family 3890. Affymetrix 100 K AGH is shown with 
a 59 SNP window, and Affymetrix 500 K AGH is shown with a 170 SNP window. Note duplication at 111,442,951 to 
113,003,770 bp that is apparent on 500 K AGH but was not called on our original analysis of the 100 K AGH data. The CNV is 
represented by 59 SNPs on the 100 K array. Lower panel: Smoothed copy number plot for chromosome 4 in Family 4840. 
Affymetrix 100 K AGH is shown with a 13 SNP window, and Affymetrix 500 K AGH is shown with a 145 SNP window. Note 
deletion at 1,346,924 to 2,846,261 bp that is apparent on 500 K AGH but was not called as de novo by 100 K AGH on our ini-
tial analysis. This CNV is represented by 17 SNPs on the 100 K array.BMC Genomics 2009, 10:526 http://www.biomedcentral.com/1471-2164/10/526
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have occurred by chance because we just happened to
include a few more patients with such genomic changes in
the new cohort than in the 100 K cohort, we also found
two additional de novo CNVs by 500 K GeneChip® AGH
among the 44 children whose 100 K AGH was interpreted
as normal in our earlier studies (Figure 1 and Table 3).
We detected three apparently de novo CNVs smaller than
200 kb among the 100 trios tested with 500 K GeneChip®
AGH in the new cohort (a 107 kb deletion of chromo-
some 14 in Patient 818, a 186 kb deletion of chromosome
21 in Patient 8619, and an 89 kb deletion of chromosome
6 in Patient 216 that was actually a homozygous loss
inherited from two heterozygous parents), but none of
Table 3: Genomic imbalance detected by 500K AGH in 54 idiopathic ID trios from the 100K cohort.
Affymetrix 100K AGH Affymetrix 500K AGH
Family Change Location Start → End Size (bp) Change Location Start → End Size (bp)
1895 Deletion 13q12.11-q12.13 18,867,056
→ 
24,517,730
5,650,674 Deletion 13q12.11-q12.12 18,876,037
→ 
24,330,232
5,454,195
3476 Deletion 4q21.21-q22.1 82,008,594 
→ 
93,076,278
11,067,684 Deletion 4q21.21-q22.1 82,429,950
→ 
91,434,337
9,004,387
3890 Normal Duplication 8q23.2-q23.3 111,442,951
→ 
113,003,770
1,560,819
4794 Duplication 16p13.3 925,718
→ 
3,864,938
2,939,220 Duplication 16p13.3 2,681,813
→ 
3,927,524
1,245,711
4818 Deletion 12q14.2-q15 63,342,649
→ 
66,780,095
3,437,446 Deletion 12q14.2-q15 63,362,084
→ 
66,737,699
3,375,615
4840 Normal Deletion 4p16.3 1,346,924
→ 
2,846,261
1,499,337
5003 Deletion 2p16.3 50,799,281
→ 
>51,120,644
321,363 Deletion 2p16.3 50,829,675
→ 
51,120,302
290,627
5566 Deletion 14q11.2 20,741,117
→ 
20,918,741
177,624 Deletion 14q11.2 20,787,740
→ 
20,988,716
200,976
5994 Mosaic Trisomy 9 Whole Chromosome Mosaic Trisomy 9 Whole 
Chromosome
6545 Deletion 7p22.2-p22.1 3,498,135
→ 
7,134,218
3,636,083 Deletion 7p22.2-p22.1 3,657,805
→ 
6,165,597
2,507,792
7807 Deletion 22q12.1 26,144,210
→ 
27,557,971
1,413,761 Deletion 22q12.1 26,293,416
→ 
27,462,458
1,169,042
8326 Deletion 14q11.2 19,584,863
→ 
21,207,935
1,623,072 Deletion 14q11.2 19,592,409
→ 
21,256,822
1,664,413
The table includes all de novo CNVs and mosaic trisomy detected by 500 K AGH and confirmed by an independent method in a selected group of 
54 trios who had previously been tested by 100 K GeneChip® AGH [10]. Breakpoints are shown on Human Genome Assembly Build 36.1.BMC Genomics 2009, 10:526 http://www.biomedcentral.com/1471-2164/10/526
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these CNVs was clearly pathogenic. The overall size distri-
bution of pathogenic CNVs detected by 500 K GeneChip®
AGH among 154 children with idiopathic ID in the
present study is similar to that observed by 100 K Gene-
Chip® AGH among 100 children with idiopathic ID whom
we studied previously [10] (see Additional File 2: Supple-
mental Figure S1). The higher detection rate on the 500 K
array therefore appears to be related more to better probe
coverage in relevant genomic regions and an improved
ability to distinguish CNVs from background noise, rather
than to a capacity to identify much smaller pathogenic
CNVs. This is illustrated in Families 3890 and 4840 (Fig-
ure 1), in which a 1.6 Mb duplication of 8q23.2q23.3 and
a 1.5 Mb deletion of 4p16.3, respectively, are obvious on
the 500 K AGH but were not called on the 100 K analysis.
In retrospect, the 4p16.3 deletion in Patient 4840 can be
seen on the 100 K AGH copy number plot despite the
noisy data, but it was not called by either the automated
analysis or visual inspection of these plots when the initial
study was done. Our failure to detect the de novo duplica-
tion of 8q23.2q23.3 in Patient 3890 was probably caused
by the noisy data in the father's study.
Distinguishing benign CNVs from those that cause ID and
other birth defects is a critical issue in routine clinical use
of AGH. Benign CNVs occur in all people and are a major
Uniparental disomy detected with Affymetrix 500 K AGH in two patients with idiopathic ID Figure 2
Uniparental disomy detected with Affymetrix 500 K AGH in two patients with idiopathic ID. A) The child in Family 
6904 was found to have mosaic paternal uniparental disomy, probably isodisomy, of chromosome 11 p15.5-p11.2. SNP genotypes 
obtained by Affymetrix 500 K AGH and interpreted for the trio as described in the Methods are shown along the length of chro-
mosome 11. B) The child in Family 1658 was found to have maternal uniparental disomy for all of chromosome 16. The ends of 
both chromosome arms (proximal to 11,559,620 bp and distal to 84,641,383 bp) appear to be isodisomic; the central portion of 
the chromosome is heterodisomic. SNP genotypes obtained by Affymetrix 500 K AGH and interpreted for the trio as described 
in the Methods are shown along the length of chromosome 16. C) Allelic imbalance, compatible with paternal isodisomy and 
mosaicism, for two informative microsatellite markers in the involved region of chromosome 11 in the child in Family 6904. The 
location of each marker is shown in brackets. D) Maternal heterodisomy for two informative microsatellite  markers in the 
involved region of chromosome 16 in the child in Family 1658. The location of each marker is shown in brackets.BMC Genomics 2009, 10:526 http://www.biomedcentral.com/1471-2164/10/526
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source of genetic variation in the normal population
[21,27,29]. Most apparently benign CNVs over 2 kb in
size occur as polymorphisms with minor allele frequen-
cies of at least 5% [21] and are inherited from a parent
[21,23,45,46].
Benign and pathogenic CNVs can usually be distinguished
in patients with ID and other birth defects by inheritance
and genotype-phenotype correlation [5,33,47]. In this
study, we identified a mean of about 10 CNVs per subject
in the 154 ID trios tested by 500 K AGH. The vast majority
of these CNVs were characterized as benign because they
were inherited from a normal parent. Genomic imbalance
that occurs de novo in a patient with ID whose parents are
normal is more likely to be pathogenic than genomic
imbalance that was inherited unchanged from a normal
parent. We performed AGH on both parents of every child
with ID to determine the inheritance of the CNVs found
in the child, but this is sometimes not possible in clinical
practice. In such instances it is necessary to infer likely de
novo occurrence by information obtained from popula-
tions that have previously been studied [19,22-24,48,49].
Great care must be taken to avoid misinterpretation when
this is done, especially if the available data were obtained
with lower resolution AGH, the phenotypic characteristics
of the comparison population are uncertain, reported pol-
ymorphic CNVs do not have exactly the same breakpoints
as the CNV of interest, or the population frequency of a
previously-reported CNV is unknown.
Compelling evidence that a CNV in a person with ID is
pathogenic exists if the genomic imbalance is known to
cause the patient's phenotype in other individuals, e.g., if
a child with del 9q34.3 has features of the 9q subtelom-
eric deletion syndrome (Patient 523), a child with del
1p36.32p36.33 has features of the 1p36 deletion syn-
drome (Patient 9133), or a child with del 17q21.31 has
features of the syndrome associated with this deletion
(Patient 2106). Pathogenicity is also supported when a
CNV includes a gene that is known to cause the patient's
phenotype when inactivated (if the CNV is a deletion) or
over-expressed (if the CNV is a duplication). On the other
hand, a CNV is unlikely to be pathogenic if it involves a
highly polymorphic region in which genomic loss (or
gain, whichever is present in the patient) of the entire
involved segment is known to occur in normal people.
If a direct genotype-phenotype correlation of this kind
cannot be made in a particular case, certain genetic fea-
tures of the CNV may provide clues to its pathogenicity.
CNVs that are larger and those that involve gene-rich
regions are more likely to be pathogenic than CNVs that
are smaller and involve only gene-poor regions [5,47]. In
addition, clinical experience suggests that deletions are
more likely to be pathogenic than duplications [47]. The
genetic content of a CNV may also make pathogenicity
more or less likely. For example, involvement of a gene
that lies within a pathway that is known to contain other
dosage-sensitive genes associated with a similar pheno-
type strengthens the possibility of pathogenicity, while a
CNV that does not contain any genes that are expressed in
relevant tissues during embryogenesis is unlikely to be
pathogenic for ID.
There are, of course, exceptions to each of these "rules".
Some benign CNVs arise de novo [21,23,45,46,50], as
appears to have occurred in the de novo deletion of chro-
mosome 14q11.2 we found in Patient 818. The 107 kb
region involved is highly polymorphic and contains sev-
eral T-cell receptor variable region genes. On the other
hand, some CNVs that are inherited from a normal parent
are pathogenic for ID. Examples include maternal trans-
Table 4: UPD detected in 100 children with idiopathic ID from the new cohort.
Patient Chromosome Affected Region SNPs in Region of UPD Interpretation
Start End Size (bp) Total Paternal UPD Maternal UPD BPI* MI*
6904 11 196,767 44,589,530 44,392,763 9,857 h = 192*
i = 456*
h = 89
i = 1
59 8 Paternal 
Isodisomy
1658 16 14,139 11,559,620 11,545,481 2,837 h = 0
i = 1
h = 193
i = 188
5 19 Maternal 
Isodisomy
11,559,620 84,641,380 73,081,760 11,698 h = 0
i = 0
h = 638
i = 3
12 95 Maternal 
Heterodisomy
84,641,383 88,668,856 4,027,473 772 h = 0
i = 0
h = 25
i = 56
1 7 Maternal 
Isodisomy
The table includes all UPD detected by 500 K GeneChip® AGH and confirmed by an independent method in 100 children with idiopathic ID. All 
mendelian inconsistencies observed were single. SNPs that are not listed as paternal UPD, maternal UPD, BPI* or MI* were uninformative with 
respect to UPD. Breakpoints are shown on Human Genome Assembly Build 36.1.
* Abbreviations used: h = heterodisomy, i = isodisomy, BPI = biparental inheritance, MI = mendelian inconsistency.BMC Genomics 2009, 10:526 http://www.biomedcentral.com/1471-2164/10/526
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mission of a UBE3A deletion to a child with Angelman
syndrome [51], maternal transmission of a MECP2 dupli-
cation to a son [52], and CNVs such as dup 22q11.2
[53,54] or del 1q21.2 [55] that can cause ID but exhibit
incomplete penetrance.
Although large (> 250 kb) CNVs are often pathogenic,
they may be benign [19,29]. Most benign CNVs are small
(< 250 kb) [19,27,29], and it seems probable that the
smaller a CNV, the more likely it is to be benign. Never-
theless, no clear size distinction exists between benign
and pathogenic CNVs. We found pathogenic CNVs as
small as the 298 kb deletion of 9q34.3 in Patient 523 in
this study, and others have reported even smaller patho-
genic CNVs [13-15,56-58]. Expression patterns, func-
tional annotation and animal models can provide
important clues to pathogenicity in some cases, but with-
out knowledge of the phenotypic effects of a copy number
alteration in humans, one can rarely, if ever, be certain
whether a novel gain or loss of a particular genomic
region can produce ID or other birth defects.
In our 500 K AGH study of 154 ID trios, 58 de novo CNVs
were called by bioinformatic analysis, and 33 of these
CNVs were confirmed and shown to be de novo by an inde-
pendent method. Because we could assess the phenotypes
of our patients in detail and correlate the findings with
those obtained by AGH, we were able to determine with
confidence whether the genomic imbalance we observed
was pathogenic or not in every case studied except three
(Tables 2 and 3). Such genotype-phenotype correlation is
critical to determining the effects of novel CNVs detected
by AGH in patients with ID.
A CNV of uncertain clinical significance was encountered
in three (1.9%) of the 154 trios analyzed in this series - a
362 kb duplication of 22q11.21 in Patient 9979 (Table 2),
a 186 kb deletion of 21q22.11 in Patient 8619 (Table 2)
and a 1.6 Mb duplication of chromosome 8q23.2q23.3 in
Patient 3890 (Table 3). This rate of CNVs of uncertain
clinical significance is similar to that reported in large
series of patients with ID and other birth defects studied
by AGH with "targeted" chips [31,35,59].
We were uncertain of the clinical significance of either
case of UPD that we detected. Although only a few live-
born children with UPD 16 have been recognized, the
reported experience does not suggest that UPD 16 can
cause the abnormalities observed in Patient 1658 [60,61].
Paternal UPD 11p15 can produce Beckwith-Wiedemann
syndrome [62], but this phenotype is very different from
that observed in the affected child in Family 6904. How-
ever, as both of these cases involved isodisomy of a por-
tion of the chromosome, we cannot rule out the
possibility that the abnormal phenotype was produced by
homozygosity for a recessive mutant allele [63,64].
Although the detection of UPD in addition to alterations
of copy number is a theoretical benefit of using an array
that includes probes for SNPs, the clinical utility of
genome-wide screening for UPD in patients with idio-
pathic ID and other birth defects is uncertain.
We detected more pathogenic CNVs with 500 K AGH than
with 100 K AGH, but some CNVs that were present among
our patients were not detected using the 500 K assay. For
example, our 500 K GeneChip® analysis failed to identify
a pathogenic 83 kb deletion of chromosome 16p13.3
(3,862,993 bp to 3,945,522 bp) involving the CREBBP
gene (Patient 5121). This de novo deletion was found by
AGH on the Agilent® 244 K platform and was confirmed
by MLPA. The patient is an 8 year-old boy whose clinical
features are characteristic of the Rubinstein-Taybi syn-
drome, which has been associated with deletions and
other mutations of CREBBP in other patients [65,66]. The
83 kb genomic region deleted in our patient is poorly rep-
resented on the 500 K GeneChip® arrays, with a total of
only 15 SNPs. SNP arrays have uneven genomic coverage,
and the addition of non-polymorphic oligonucleotide
probes to the design of arrays like the one used in this
study has been shown to provide substantially better
detection of CNVs [21].
Conclusion
Affymetrix GeneChip® 500 K array genomic hybridization
performed in individuals with idiopathic intellectual dis-
ability detected pathogenic genomic imbalance in 10 of
10 patients in whom 100 K GeneChip® array genomic
hybridization found genomic imbalance, 1 of 44 patients
in whom 100 K GeneChip® array genomic hybridization
had found no abnormality, and 16 of 100 patients who
had not previously been tested. Further improvements in
array design, ongoing improvements in AGH software,
and continuing enhancement of resources like DECI-
PHER https://decipher.sanger.ac.uk/ and the Toronto
Database of Genomic Variants http://projects.tcag.ca/var
iation/ are helping to establish AGH as the primary clini-
cal tool for recognition of genomic imbalance that causes
ID and other birth defects [33,34,37,41,67-70]. It seems
likely, however, that no perfect AGH platform for detec-
tion of pathogenic CNVs may ever exist and that effective
clinical interpretation of these studies will continue to
require considerable skill and experience [33,50,71].
Methods
Patients and Families
We studied 100 children with idiopathic ID who had not
been studied by AGH before ("the new cohort") and 54 of
the idiopathic ID patients whom we had previously tested
with 100 K Affymetrix GeneChip®  AGH ("the 100 K
cohort"). Ten of the 54 patients in the 100 K cohort had
previously been found to have pathogenic genomic
imbalance; the other 44 patients had previously beenBMC Genomics 2009, 10:526 http://www.biomedcentral.com/1471-2164/10/526
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reported to have normal 100 K GeneChip® AGH (see
Additional File 1: Supplemental Table S1) [10,16]. We
also performed 500 K AGH on both unaffected parents of
each child.
All of the children were assessed by a clinical geneticist
who was unable to determine the cause of the ID despite
thorough clinical evaluation and testing that included
routine karyotyping with at least 450-band resolution.
Subjects were selected for AGH testing because they had
ID or developmental delay and at least one of the follow-
ing additional clinical features: one major malformation,
microcephaly, abnormal growth, or multiple minor
anomalies. Informed consent was obtained from each
family, and assent was also obtained from the child, if
possible. The study was approved by the University of
British Columbia Clinical Research Ethics Board.
DNA Preparation
DNA was extracted from whole blood with a Gentra Pure-
gene DNA Purification Kit (Qiagen, Hilden, Germany)
according to the manufacturer's instructions. The DNA
was precipitated in 70% alcohol, resuspended in hydra-
tion solution, and stored at 4°C.
Hybridization to GeneChip® Mapping 500 K Arrays
DNA degradation, labeling, hybridization, and scanning
were performed according to the manufacturer's protocols
http://www.affymetrix.com using an Affymetrix Fluidics
Station 450, Affymetrix Hybridization Oven 640 and
Affymetrix GeneChip Scanner 3000 (Affymetrix, Inc.,
Santa Clara, CA, USA).
Copy Number Analysis
Chip-to-chip normalization, standardization to a refer-
ence, genotype detection, and copy number estimation on
a single SNP basis were performed using the Affymetrix
Power Tools (version 1.6.0) software suite http://
www.affymetrix.com, as previously described [30]. Esti-
mation of CNV boundary positions was done using Sig-
nificance of Mean Difference (SMD), a method that we
developed. Briefly, the mean of SNP copy number esti-
mates (or log2 ratios) within a CNV was compared to the
mean of those on the rest of the chromosome, and the
probability that the null hypothesis of Student's t-test was
true, i.e., that the means were from the same distribution,
was calculated. A search using this statistic was conducted
over different CNV lengths to find the position and length
(in number of SNPs) that yielded the lowest probability,
defining the boundaries of a putative CNV. For each sam-
ple, a random data set was produced by shuffling the
genomic positions of the data, and an identical search was
conducted. The results of this search represent false dis-
coveries due to the random variation of the individual
SNP data.
The p-value distribution of apparent CNVs detected by
SMD in all 462 samples (both normal parents and the
affected child from 154 ID trios) is shown in Figure 3. We
observed that a CNV call with a p-value of 1 × 10-8 usually
had a false discovery rate of less than 5%, while a call with
a p-value of 1 × 10-7 often had a false discovery rate of
30%, with some variation from sample to sample.
Since SMD compares a putative CNV to the rest of the
chromosome, aberrations on the X chromosome are
detected equivalently well for males and females. The
pseudo-autosomal regions of the X-chromosomes are
exceptions, but CNVs there can be detected as a function
of the reference set used in the analysis. GeneChip® 500 K
arrays do not contain Y-chromosome probes.
The SMD search was performed on each child with each
parent as a reference. Since our goal was to find duplica-
tions and deletions that were de novo, a criterion for selec-
tion of CNVs for further analysis was that the child have
the same aberration with each parent as reference. Correct
parental relationships were confirmed in all trios by use of
the SNP genotyping calls.
P-value distribution of apparent CNVs detected by SMD in  462 samples from 154 ID trios Figure 3
P-value distribution of apparent CNVs detected by 
SMD in 462 samples from 154 ID trios. Data are from 
the analysis performed by 500 K GeneChip® AGH. Some of 
these apparent CNVs were merged into larger CNVs at a 
later stage of the analysis, but most represent individual aber-
rations. Apparent CNVs with p-values less than 1 × 10-8 were 
analysed further to determine if they were inherited or had 
occurred de novo. 4577 apparent CNVs were found with p-
values below this threshold (shown in blue in the figure). The 
bin plotted at 10-17 actually contains all CNVs with p < 10-16, 
which is the lower limit of the tables used to calculate p-val-
ues.BMC Genomics 2009, 10:526 http://www.biomedcentral.com/1471-2164/10/526
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Every putative de novo CNV call was evaluated by another
analysis conducted using a large reference set of individu-
als. Early in the study, the 48 sample reference set availa-
ble from Affymetrix was used, but later a set of 50 mothers
from our own data was used. The use of a local reference
set significantly reduced noise. The use of the large refer-
ence set was required to detect the occurrence of aberra-
tions in both parents that were not inherited by the child.
Putative de novo CNVs were further evaluated by visual
examination of the copy number plots in comparison to
both parents as well as of the plots for the child and both
parents in comparison to the large reference set.
Validation of De Novo CNVs
Putative de novo CNVs identified by 500 K AGH were val-
idated by fluorescence in situ hybridization (FISH) or mul-
tiplex ligation-dependant probe amplification (MLPA),
Agilent® 244 K AGH, or repeat cytogenetic analysis. FISH
was performed with BAC or fosmid probes selected using
the University of California at Santa Cruz Genome
Browser [72] and the May 2006 assembly of the human
genome sequence. BAC or fosmid DNA was isolated by
small-scale (miniprep) preparation and was labeled with
Spectrum Red or Green (Vysis, Abbott Molecular, Abbott
Park, IL, USA) by use of a Vysis nick translation reagent
kit. The labeled product was mixed with 3 mg of human
Cot-1 DNA (Invitrogen, Life Technologies Corporation,
Carlsbad, CA, USA) and was isolated by means of a stand-
ard DNA precipitation method. Cytogenetic pellets were
prepared according to standard clinical procedures, and
chromosomes and nuclei were visualized by counterstain-
ing with 4',6-diamidino-2-phenylindole. For deletions, at
least 10 metaphase cells were analyzed, and interphase
nuclei were examined but not counted. For duplications,
at least 10 metaphase cells and at least 50 interphase
nuclei were analyzed. All FISH probes were tested on met-
aphase spreads from unaffected individuals to assure
proper hybridization.
MLPA was performed using the P070 subtelomeric kit
(MRC Holland, Amsterdam, The Netherlands); all posi-
tive results were confirmed with another kit (P036B). The
procedure was conducted according to the manufacturer's
recommendations. Briefly, the patient's DNA was diluted
in PCR-grade water and quality was assessed via spectro-
photometry (Nanodrop®, Thermo Scientific, Wilmington,
DE, USA). The hybridization solution (SALSA probe-mix
and MLPA buffer) was added to a final DNA concentra-
tion of 60 ng/μl. DNA was denatured at 90°C, then
hybridized for 16-20 hours at 60°C. Ligation was per-
formed at 54°C for 15 minutes, and the ligated product
was denatured at 98°C for 5 minutes and then amplified
by PCR (SALSA PCR buffer, PCR-primers and polymer-
ase). The PCR product was run for fragment analysis on an
ABI 3130 sequencer (Applied Biosystems, Life Technolo-
gies, Carlsbad, CA, USA). Normalization of the data and
analysis of the MLPA results were conducted using Coffa-
lyser v3.5 software provided by MRC Holland (Amster-
dam, The Netherlands).
AGH was performed with Agilent® 244 K oligonucleotide
arrays (Agilent Technologies Inc., Santa Clara, CA, USA)
according to the manufacturer's instructions. Two arrays
were used for each trio, one in which the child's DNA was
hybridized against the father's DNA, and another in
which the child's DNA was hybridized against the
mother's DNA. Captured images were analysed with Fea-
ture Extraction v 9.1 and CGH Analytics 3.5.14 (Agilent
Technologies Inc., Santa Clara, CA, USA).
Cytogenetic analysis was performed on peripheral blood
cultures after preparation and G-banding of metaphase
chromosomes using standard clinical methods.
Uniparental Disomy (UPD)
Given the genotypes for the child, mother, and father,
errors in mendelian transmission were identified and
their frequency compared to normal or technical error
rates, which were very low. Essentially, the occurrences of
an AA parent with a BB child, or vice versa, were counted.
Graphical tools were developed to distinguish heterodis-
omy and isodisomy by visualization and to determine the
parent of origin [30].
Confirmation of uniparental disomy was obtained by
genotyping microsatellite markers chosen for high hetero-
zygosity values. The following markers were genotyped
and were informative for chromosome 11: D11S1363
(AFMA134WH5), D11S4046 (AFMB042YF5), D11S1318
(AFM218XE1), D11S4088 (AFMA155TE9) and
D11S4146 (AFMB072WE5). The following markers were
genotyped and were informative for chromosome 16:
D16S3093 (AFMB308ZH9), D16S409 (AFM161XA1),
D16S515 (AFM340YE5) and D16S402 (AFM031XA5). 25
ng of DNA diluted in 10:1 TE buffer were amplified for
each PCR reaction. Primers fluorescently labeled with
either 6-fam or HEX (Applied Biosystems, Life Technolo-
gies, Carlsbad, CA, USA) were used in conjunction with
AmpliTaq Gold® PCR kit reagents (Applied Biosystems,
Life Technologies, Carlsbad, CA, USA). PCR was per-
formed using the following steps: 95°C for 10 minutes;
30 cycles of 95°C for 30 seconds, 55°C for 30 seconds,
and 72°C for 90 seconds; and a final step at 72°C for 7
minutes. The resulting PCR product in a volume of 1 μl
was combined with 9 μl formamide (Applied Biosystems,
Life Technologies, Carlsbad, CA, USA) and 0.3 ul GeneS-
can ROX 500 (Applied Biosystems, Life Technologies,
Carlsbad, CA, USA), denatured at 95°C for 5 minutes,
quickly chilled in ice and loaded onto a Genetic Analyzer
3130XL (Applied Biosystems, Life Technologies,BMC Genomics 2009, 10:526 http://www.biomedcentral.com/1471-2164/10/526
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Carlsbad, CA, USA). Data were visualized using GeneMa-
pper v4.0 (Applied Biosystems, Life Technologies,
Carlsbad, CA, USA).
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